Impact of FGFR4 Gene Polymorphism on the Progression of Colorectal Cancer

Shiu, Bei-Hao; Hsieh, Ming‐Hong; Ting, Wen-Chien; Chou, Ming‐Chih; Chang, Lun‐Ching; Huang, Chi‐Chou; Su, Shih‐Chi; Yang, Shun‐Fa

doi:10.3390/diagnostics11060978

Cited by 10 publications

(12 citation statements)

References 34 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the remaining 87 potentially eligible studies, 43 which did not meet the eligible criteria were further excluded. Finally, 44 studies were selected for the qualitative synthesis ( 9 , 12 – 18 , 21 , 23 – 27 , 34 – 45 , 47 – 53 , 55 – 65 ).…”

Section: Resultsmentioning

confidence: 99%

“…However, other researchers have reported contrasting results in several cancer types ( 43 – 46 ). There have also been many studies that failed to observe any significant contribution of the FGFR4 Gly388Arg SNP to the clinicopathological parameters or prognosis in patients with cancer ( 13 , 14 , 16 , 17 , 21 , 23 , 26 , 27 , 35 , 47 – 65 ). Therefore, the prognostic impact of the FGFR4 Gly388Arg polymorphism in cancer patients still remains controversial.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

The fibroblast growth factor-4 receptor (FGFR4) is a member of receptor tyrosine kinase. The FGFR4 Gly388Arg polymorphism in the transmembrane domain of the receptor has been shown to increase genetic susceptibility to cancers. However, its prognostic impact in cancer patients still remains controversial. Herein, we performed this meta-analysis to evaluate the clinicopathological and prognostic impacts of the FGFR4 Gly388Arg polymorphism in patients with cancer. We carried out a computerized extensive search using PubMed, Medline, and Ovid Medline databases up to July 2021. From 44 studies, 11,574 patients were included in the current meta-analysis. Regardless of the genetic models, there was no significant correlation of the FGFR4 Gly388Arg polymorphism with disease stage 3/4. In the homozygous model (Arg/Arg vs. Gly/Gly), the Arg/Arg genotype tended to show higher rate of lymph node metastasis compared with the Gly/Gly genotype (odds ratio = 1.21, 95% confidence interval (CI): 0.99-1.49, p = 0.06). Compared to patients with the Arg/Gly or Arg/Arg genotype, those with the Gly/Gly genotype had significantly better overall survival (hazard ratios (HR) = 1.19, 95% CI: 1.05-1.35, p = 0.006) and disease-free survival (HR = 1.25, 95% CI: 1.03-1.53, p = 0.02). In conclusion, this meta-analysis showed that the FGFR4 Gly388Arg polymorphism was significantly associated with worse prognosis in cancer patients. Our results suggest that this polymorphism may be a valuable genetic marker to identify patients at higher risk of recurrence or mortality.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…[31] Higher B-GAL activity reflects the ability of cancer to accelerate growth, invasion, metastasis and maturation. [32] Serum B-GAL activity is higher in colon cancer patients with a history of alcohol and nicotine dependence compared to colon cancer patients without a history of alcohol or tobacco use, and thus the prognosis may be poorer for patients with a previous history of tobacco and alcohol use, especially in those who have not quit smoking and alcohol during is disease course and postoperatively. [33] In addition, smoking may have an effect on serum levels of carcinoembryonic antigen, which may have an impact on prognosis, and it has also been shown that smoking suppresses the immune system and affects the functioning of immune cells, thus causing immune escape of tumor cells.…”

Section: Discussionmentioning

confidence: 99%

A correlation study affecting survival in patients after radical colon cancer surgery: A retrospective study

Wei

Zhong

et al. 2023

Medicine

View full text Add to dashboard Cite

The objective of this study was to explore the relevant factors affecting the 5-year survival rate of patients after radical colon cancer surgery, and to provide some basis for improving the quality of life and prognosis of colon cancer patients. The clinical data of 116 colon cancer patients who underwent treatment in our hospital from January 2017 to December 2017 were retrospectively selected. Using the date of performing surgical treatment as the starting point and the completion of 5 years after surgery or patient death as the end point, all patients were followed up by telephone to count the 5-year survival rate and analyze the influence of each factor with the prognosis of colon cancer patients. Of the 116 patients, 14 patients were lost to follow-up. Of the 102 patients with complete follow-up, 33 patients were died, with an overall 5-year survival rate of 67.6%. After univariate analysis, it was found that distant metastasis (χ2 = 10.493, P = .001), lymph node metastasis (χ2 = 25.145, P < .001), depth of muscle infiltration (χ2 = 14.929, P < .001), alcohol consumption (χ2 = 15.263, P < .001), and preoperative obstruction (χ2 = 9.555, P = .002) were significantly associated with the prognosis of colon cancer patients. Multivariate logistic analysis showed that distant metastasis (odds ratio [OR]: 1.932, 95% confidence intervals [CI]: 1.272–2.934, P = .002), lymph node metastasis (OR: 1.219, 95% CI: 1.091–1.362, P < .001), and obstruction (OR: 1.970, 95% CI: 1.300–2.990, P < .001) were significant independent risk factors affecting the prognosis in patients after radical colon cancer surgery. In summary, preoperative obstruction, lymph node metastasis, and distant metastasis are independent factors influencing 5-year survival rate after radical colon cancer surgery. Patients with risk factors should be followed up more closely and reasonable postoperative adjuvant chemotherapy regimens should be used to improve long-term survival.

show abstract

“…FGF7, also called keratinocyte growth factor (KGF), is involved in inducing vascular endothelial growth factor (VEGF)-A expression, which plays important roles in the angiogenesis and metastasis of various cancer cells including colorectal cancer (51,52). FGFR4, a receptor tyrosine kinase, plays a key role in cancer development and prognosis via the activation of its downstream oncogenic signaling pathways (53).…”

Section: Discussionmentioning

confidence: 99%

Development and validation of immune-related genomics nomogram for prognostic prediction in left- and right-side colorectal cancer

Niu

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Previous studies have reported that the tumor heterogeneity and immune molecular mechanisms of proximal and distal colorectal cancer (CRC) are divergent. Therefore, our study aims to analyze the difference between left-sided CRC (LCC) and right-sided CRC (RCC), and respectively develop the nomograms based on prognostic immune-related genes for LCC and RCC. Methods: We enrolled 443 colon cancer patients (220 LCC patients and 223 patients) from The Cancer Genome Atlas (TCGA) datasets. Firstly, the differential expressed immune-related genes (DE-IRGs), overall survival (OS), and biological functions between LCC and RCC groups were identified. Then, we analyzed the differences between the two groups in the immune microenvironment, immune checkpoint, and tumor mutation burden (TMB). Next, the LCC and RCC data from TCGA dataset are randomly divided into training and internal validation sets at a 7:3 ratio respectively. Additionally, 566 colon cancer patients (342 LCC patients and 224 RCC patients) in the GSE39582 dataset were downloaded from the Gene Expression Omnibus (GEO) database as the external validation set. Then, survival and Lasso Cox regression analyses were applied to identify hub immune-related genes and respectively establish two prognostic gene signatures of LCC and RCC groups. The prognostic signatures were validated by the 10-fold cross-validation, internal validation set, and external validation set. Further, combined with clinical features, we constructed two clinical predictive nomograms and validated them. Results: RCC patients have lower survival than LCC. RCC patients have higher proportions of T cells CD8, T cells follicular helper, and lower macrophages M0, T cells CD4 naive. RCC patients have higher ESTIMATE and immune scores and lower tumor purity. The immune checkpoint expression levels and TMB values are higher in RCC patients than in LCC. We respectively selected 10 immune-related genes for LCC and 7 genes for RCC groups to develop and validate the prognostic model and calculate a risk score for each patient. The AUC values of the risk score for OS in LCC were 0.735 in the training set, 0.711 in the internal validation set, and 0.744 in the external validation set, and in RCC were 0.704 in the training set, 0.738 in the internal validation set, and 0.705 in the external validation set. The AUC values of the 10-fold cross-validation range from 0.564 to 0.808 in LCC and from 0.589 to 0.792 in RCC. The nomogram of LCC of RCC includes risk based on prognostic genes, age, pathological T, N, M, stage, and gender. the AUC values of the LCC nomogram were 0.722 in the training set, 0.696 in the internal validation set, and 0.739 in the external validation set, and of the RCC nomogram were 0.774 in the training set, 0.744 in the internal validation set, and 0.737 in the external validation set. We also found that were significantly different between high- and low-risk patients in the immune score, ESTIMATE score, tumor purity, immune checkpoint expression levels, and TMB values. Conclusions: We found significant differences in the multidimensional insight between LCC and RCC patients in clinical features, DE-IRGs, TMB, immune checkpoint expression levels, and immune microenvironment landscape. Our study respectively established two prognostic nomograms based on DE-IRGs in combination with clinical features to provide a basis for personalized and precise treatment of LCC and RCC patients.

show abstract

Impact of FGFR4 Gene Polymorphism on the Progression of Colorectal Cancer

Cited by 10 publications

References 34 publications

FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis

FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis

A correlation study affecting survival in patients after radical colon cancer surgery: A retrospective study

Development and validation of immune-related genomics nomogram for prognostic prediction in left- and right-side colorectal cancer

Contact Info

Product

Resources

About